MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model

Gut

Volumn 65, Issue 3, 2016, Pages 465-475

  Serrao, Eva M ^a   Kettunen, Mikko I ^a,b   Rodrigues, Tiago B ^a   Dzien, Piotr ^a   Wright, Alan J ^a   Gopinathan, Aarthi ^a   Gallagher, Ferdia A ^a   Lewis, David Y ^a   Frese, Kristopher K ^c   Almeida, Jaime ^a   Howat, William J ^a   Tuveson, David A ^d   Brindle, Kevin M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Simons Center for Quantitative Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALANINE AMINOTRANSFERASE; CARBON 13; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE; HEXOKINASE 1; HEXOKINASE 2; LACTATE DEHYDROGENASE; LACTIC ACID; PYRUVATE CARBON 13; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PYRUVIC ACID;

ADVANCED PANCREATIC PRENEOPLASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MODEL; CANCER STAGING; CARBON NUCLEAR MAGNETIC RESONANCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC ENGINEERING; GLUCOSE TRANSPORT; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERPOLARIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATITIS; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSGENIC MOUSE; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; DISEASE COURSE; EVALUATION STUDY; METABOLISM; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES;

ANIMALS; BIOMARKERS; CARBON-13 MAGNETIC RESONANCE SPECTROSCOPY; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; MICE; MICE, TRANSGENIC; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; PRECANCEROUS CONDITIONS; PYRUVIC ACID;

EID: 84960382980     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310114     Document Type: Article

References (45)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol 1996;23:241-50.
4. Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005;128:1626-41.
5. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol 2007;34:284-94.
6. Hermanova M, Nenutil R, Kren L, et al. Proliferative activity in pancreatic intraepithelial neoplasias of chronic pancreatitis resection specimens: detection of a high-risk lesion. Neoplasma 2004;51:400-4.
7. Hruban RH, Adsay NV, Albores-Saavedra J, et al Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-86.
8. Maitra A, Fukushima N, Takaori K, et al. Precursors to invasive pancreatic cancer. Adv Anat Pathol 2005;12:81-91.
9. Volkholz H, Stolte M, Becker V. Epithelial dysplasias in chronic pancreatitis. Virchows Arch 1982;396:331-49.
10. Feldmann G, Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 2008;10:111-22.
11. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-47.
12. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
13. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-75.
14. Fang F, He X, Deng H, et al. Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer Sci 2007;98:1678-82.
15. Cho SG, Lee DH, Lee KY, et al. Differentiation of chronic focal pancreatitis from pancreatic carcinoma by in vivo proton magnetic resonance spectroscopy. J Comput Assist Tomogr 2005;29:163-9.
16. Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 2007;34:303-10.
17. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2:606-21.
18. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of >10, 000 times in liquid-state NMR. Proc Natl Acad Sci USA 2003;100:10158-63.
19. Day SE, Kettunen MI, Gallagher FA, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007;13:1382-7.
20. Albers MJ, Bok R, Chen AP, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008;68:8607-15.
21. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
22. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83.
23. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
24. Fendrich V, Schneider R, Maitra A, et al. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer1. Neoplasia 2011;13:180-6.
25. Algul H, Treiber M, Lesina M, et al. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J Clin Invest 2007;117:1490-501.
26. Vassault A. Lactate dehydrogenase. UV-method with pyruvate and NADH. In: H. U. Bergmeyer, ed. Methods of enzymatic analysis 1983;3:118-26.
27. Wu H, Southam AD, Hines A, et al. High-throughput tissue extraction protocol for NMR- and MS-based metabolomics. Anal Biochem 2008;372:204-12.
28. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149:656-70.
29. Olson P, Chu GC, Perry SR, et al. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci USA 2011;108:E1275-84.
30. Kaluz S, Kaluzova M, Liao SY, et al. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 2009;1795:162-72.
31. Witney TH, Kettunen MI, Brindle KM. Kinetic modeling of hyperpolarized 13C label exchange between pyruvate and lactate in tumor cells. J Biol Chem 2011;286:24572-80.
32. Harrison C, Yang C, Jindal A, et al. Comparison of kinetic models for analysis of pyruvate-to-lactate exchange by hyperpolarized 13 C NMR. NMR Biomed 2012;25:1286-94.
33. Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res 1964;24:389-99.
34. Hu S, Balakrishnan A, Bok RA, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 2011;14:131-42.
35. Eser S, Messer M, Eser P, et al. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci USA 2011;108:9945-50.
36. Neesse A, Hahnenkamp A, Griesmann H, et al. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut 2013;62:1034-43.
37. Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 2011;17:302-9.
38. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-17.
39. Konstantinidis IT, Vinuela EF, Tang LH, et al. Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance? Ann Surg Oncol 2013;20:3643-7.
40. Sakorafas GH, Tsiotos GG, Korkolis D, et al. Individuals at high-risk for pancreatic cancer development: management options and the role of surgery. Surg Oncol 2012;21:e49-58.
41. Shi C, Klein AP, Goggins M, et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009;15:7737-43.
42. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. AFIP atlas of tumor pathology. Washington, DC: American Registry of Pathology/Armed Forces Institute of Pathology, 2007.
43. de Graaff CS, Taylor KJ, Simonds BD, et al. Gray-scale echography of the pancreas. Re-evaluation of normal size. Radiology 1978;129:157-61.
44. 13C]pyruvate. Sci Transl Med 2013;5:198ra08.
45. 13C]pyruvic acid at 4.6 tesla. J Magn Reson 2009;197:167-75.